Mirum Pharmaceuticals (MIRM) FCF Margin (2021 - 2026)

Mirum Pharmaceuticals' FCF Margin history runs 6 years deep, the most recent figure standing at 143.5% for Q1 2026.

• In Q1 2026, FCF Margin fell 14170.0% year-over-year to 143.5%; the TTM figure through Mar 2026 stood at 30.29% (down 2822.0% YoY), while the FY2025 annual figure was 10.53%, up 776.0% from the prior year.
• FCF Margin was 143.5% for Q1 2026 at Mirum Pharmaceuticals, down from 3.67% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 29.69% in Q3 2025 to a low of 307.7% in Q1 2022.
• Historically, FCF Margin has averaged 55.35% across 5 years, with a median of 23.89% in 2023.
• The sharpest annual moves came in 2022 and 2026: FCF Margin jumped 93273 bps in 2022, then tumbled 14170 bps in 2026.
• A 5-year view of FCF Margin shows it stood at 123.67% in 2022, then jumped by 81 bps to 23.89% in 2023, then jumped by 79 bps to 5.12% in 2024, then soared by 172 bps to 3.67% in 2025, then plunged by 4009 bps to 143.5% in 2026.
• The last three FCF Margin figures came in at 143.5% (Q1 2026), 3.67% (Q4 2025), and 29.69% (Q3 2025), per Business Quant data.